Background: The antifolate edatrexate and the microtubulestabilizing agent paclitaxel have both demonstrated singleagent activity in lung and breast cancer. In vitro, the sequential combination of edatrexate followed by paclitaxel produced synergistic antitumor effects. This trial was designed to find the maximum tolerated doses of edatrexate and paclitaxel when given every two weeks utilizing this sequential schedule.
Introduction
After drugs demonstrate antitumor activity in singleagent trials, a dose-ranging combination trial follows to ideally define a regimen delivering each agent at its phase II dosage. The use of in vitro data has been proposed as another method to design chemotherapy combinations [1] . This study of edatrexate (EDX; 10-ethyi-10-deazaaminopterin) and paclitaxel (PTX, Taxol®) integrates these approaches.
Edatrexate is an active anticancer agent in carcinomas of the breast, lung, bladder, head and neck, mesothelioma, and malignant fibrous histiocytoma [2, 3] . The dose-limiting adverse reaction is mucositis [4] . Paclitaxel demonstrates significant antitumor activity in carcinomas of the ovary, breast, lung, and bladder [5] . The principal dose-limiting toxicity of paclitaxel is neutropenia [5] . The effects of schedule when combining edatrexate and paclitaxel have been assessed in two human adenocarcinoma lines (SK-Br-3) and (ZR-75-1) [6] . Among the schedules tested the sequential administration of edatrexate 24 hours before paclitaxel showed the greatest synergism [6] . Since edatrexate and paclitaxel demonstrate single-agent antitumor activity against many tumor types, and the in vitro data suggested both synergy and an optimal schedule, we conducted this trial to establish the doses of edatrexate and paclitaxel when combined sequentially.
Patients and methods
All patients had pathologically confirmed solid tumors and had not received edatrexate or paclitaxel. Additional requirements: age 3= 18; Karnofsky performance status > 60%; no significant edema, ascites or pleural effusion, congestive heart failure, unstable angina, arrhythmia, or greater than NCI grade 2 neuropathy. An interval of three weeks was required after radiotherapy or chemotherapy. All patients had a leukocyte count ^4000 cells/ul, platelet count ^160,000 cells/ul, bilirubin $1.5 mg/dl and creatinine $1.5 mg/dl. Written informed consent was obtained. This Center's Institutional Review Board approved the study Edatrexate was administered in 50 ml of 0.9% sodium chloride over 20 minutes through a flowing intravenous line. Edatrexate was given on days one and 15 of a 28-day cycle. Paclitaxel was administered in a 500 ml glass bottle of 0.9% sodium chloride over three hours through polyethylene tubing and a microporous filter (IVEX-II). Paclitaxel was given on days 2 and 16 of each 28-day cycle. Patients received standard premedication with dexamethasone. diphenhydramine and cimetidine. The study was initially designed to hold the paclitaxel dose fixed at 135 mg/m 2 and to escalate edatrexate until a maximum tolerated dose (MTD) was reached or -120 mg/ra 2 -reproducing the 60 mg/m 2 /week dose intensity achieved in single-agent trials [3. 4] , When the MTD for the combination was not reached with this plan, the edatrexate was fixed at 120 mg/m 2 and paclitaxel increased. Dose escalations for edatrexate were 40, 60, 80, and 120 mg/m 2 . The starting dose of paclitaxel was 135 mg/m 2 which was subsequently escalated to 175 and 210 mg/m 2 . Dose escalation was not permitted for individual patients.
Patients were evaluated weekly for adverse events for the first cycle (28 days), then every two weeks. Standard criteria for response and indicator lesions were used. Survival and response duration were determined from the start of edatrexate. Adverse events were graded by the Common Toxicity Criteria of the National Cancer Institute. The MTD was defined as the highest doses of the combination that produced grade 3 or 4 events in 33% of the patients during the first four weeks (one cycle) of treatment. 
Results
Thirty-four patients received 135 courses. Fourteen patients received <2 courses of therapy while 10 received more than four courses. Two patients continue to receive monthly edatrexate and paclitaxel after more than 24 months. Twenty-nine percent were women and 76% had a Karnofsky performance status >80%. Twenty-five patients (74%) had non-small-cell lung cancer and 38% of them had not received chemotherapy. Twelve percent had unknown primaries. The median age was 55 (range 27-72).
Four of the seven patients who received 120 mg/m 2 of edatrexate and 210 mg/m 2 of paclitaxel experienced grade 3 toxicity during the first cycle. One had grade 3 leukopenia, one grade 3 peripheral neuropathy, one grade 3 myalgias, and one a grade 3 hypersensitivity reaction with paclitaxel. Leukopenia and diarrhea were the most frequently observed grade 3 effects (Table 1) . Two of eleven patients (18%) treated with 120 mg/m 2 of edatrexate and 175 mg/m 2 of paclitaxel developed grade 3 leukopenia. Four chemotherapy-naive patients received 120 mg/m 2 of edatrexate and 175 mg/m 2 of paclitaxel without grade 3 leukopenia on treatment days. Four patients (12%) developed grade 3 peripheral neuropathy; three of these four patients had a grade 2 peripheral neuropathy from prior vinca alkaloids or cisplatin. One chemotherapy-naive patient who received 210 mg/m 2 of paclitaxel developed a grade 3 peripheral neuropathy. All had alopecia. Thrombocytopenia, stomatitis, epistaxis, and vomiting were mild and uncommon. One patient previously treated with chemotherapy and irradiation died on study day 43 with bilateral pulmonary infiltrates, fever, leukopenia and thrombocytopenia following her second doses of edatrexate (80 mg/m 2 ) and paclitaxel (135 mg/m 2 ). Dose levels and delivered doses are summarized in Table 2 .
Responses were observed in 8 of 25 patients (32%) with non-small-cell lung cancer with a median response duration of nine months (range 5-16+ months). One previously treated patient with bladder cancer had a partial response lasting 12 months. The median survival for all patients was 13 months and the one-year survival 53%. For the 25 non-small-cell lung cancer patients, the median survival was 11 months and one-year survival 44%.
Discussion
A conventionally designed combination chemotherapy trial combines agents that have exceeded a threshold of activity in phase II studies; for example, a major response rate ^ 15% in non-small-cell lung cancer patients. The same schedule tested in the phase II trials is employed whenever possible [7] . The doses for the combination are determined by a dose-ranging trial. Usually, the dose of one of the drugs is fixed and doses of the second agent are escalated either to its phase II dose or failing that, the maximal tolerated dose possible in combination. The efficacy [8] and safety [9] of paclitaxel combinations in particular are not predictable as interactions between drugs may cause effects which differ from single-agent study results. To improve combination chemotherapy trials, preclinical models have been used to select agents, define interactions, and identify optimal schedules. The initial in vivo combination chemotherapy studies focused on mouse tumors [10] . These mouse systems defined dose-toxicity relationships and identified administration schedule and sequence as contributors to synergy [11] . In vitro quantitation of synergism has been proposed to more rationally combine active agents for patients with germ-cell tumors [1] .
This phase I trial of the combination of edatrexate and paclitaxel couples a conventional dose-ranging study design with one based on in vitro observations. Distinct single-agent growth inhibition by each drug was shown in two cell lines [6] . Edatrexate and paclitaxel have each demonstrated antitumor activity in phase II trials [2, 5] . The schedule giving edatrexate 24 hours before paclitaxel produced the greatest synergism. The inverse sequence produced antagonism.
The recommended doses and schedules from this study are edatrexate 120 mg/m 2 administered one day prior to paclitaxel 175 mg/m 2 over 3 hours on days 1-2 and 14-15 of a 28-day cycle. These doses equal or exceed the dose intensity achieved in the phase II efficacy trials of each agent [4, 5] . When administered to chemotherapynaive patients, dose attenuation, filgrastim, or treatment delays were not required and the regimen was exceptionally well tolerated. The dose-limiting leukopenia, peripheral neuropathy, myalgia, and infusion-related hypersensitivity reactions seen at higher doses were attributable to the three-hour infusion of paclitaxel. Activity was demonstrated in lung and bladder cancer.
This phase I trial showed acceptable toxicity, denned the doses of edatrexate and paclitaxel in sequential combination, and documented anticancer activity. With the preclinical rationale confirmed in this trial, this regimen merits study in phase II trials in patients with breast cancer, non-small-cell lung cancer, head and neck cancer, bladder cancer, and other tumor types where both antifolates and taxanes are useful. Studies combining edatrexate with paclitaxel in breast cancer have been initiated [12] .
